Andreas Kogelnik
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Andreas M. Kogelnik, ("Andy") MD, PhD., is an Internal Medicine and Infectious Diseases specialist, the director of the Open Medicine Institute, Mountain View, California, USA, and a member of the Scientific Advisory Board for the Open Medicine Foundation, Agoura Hills, CA.[1][2] His interests are in the bioinformatics and genomic revolution in medicine and is committed to the study of and treatment of ME/CFS and other chronic illnesses.[3][4]
Education[edit | edit source]
- MD from Emory University
- PhD in bioengineering from Georgia Tech
- Residency in Internal Medicine at Stanford University
- Fellowship in Infectious Diseases at Stanford University
Research Publications on ME/CFS[edit | edit source]
- 2013, Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.[5]
- 2011, No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected.[6]
- 2006, Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue.[7]
Articles[edit | edit source]
Talks and Interviews[edit | edit source]
- 2014, Youtube - What Works For Chronic Fatigue Syndrome
- 2014, 9th Invest in ME International ME Conference 2014 - No title of talk given
- 2014, ME/CFS Alert Episode 56: Dr. Andreas Kogelnik on the "Real Thrust" of ME/CFS Research
- 2014, ME/CFS Alert Episode 55: Interview with Dr. Andreas Kogelnik
- 17 Feb 2014, Dr. Andreas Kogelnik and Llewellyn King on Sirius XM Radio POTUS Channel 124
- 23 Jan 2014, Dr. Andreas Kogelnik, Ryan Prior and Llewellyn King appeared on “The Jim Bohannon Show”
- 2013, 8th Invest in ME International ME Conference 2013 - Key Note Speech: Strategies for ME Research and Collaboration
- 2012, ME/CFS Alert Episode 23: The Open Medicine Institute, Part 1, ME/CFS Alert Episode 23: The Open Medicine Institute, Part 2, and ME/CFS Alert Episode 23: The Open Medicine Institute, Part 3
- 2012, ME/CFS Alert Episode 22: Interview with Dr. Andreas Kogelnik, Part 1 and ME/CFS Alert Episode 22: Interview with Dr. Andreas Kogelnik, Part 2
- 2012, 7th Invest in ME International ME Conference 2012 - Strategies for ME Research and Collaboration
References[edit | edit source]
- ↑ http://www.openmedicineinstitute.org/the-clinic.html
- ↑ http://www.openmedicinefoundation.org/scientific-advisory-board/
- ↑ http://www.openmedicineinstitute.org/the-clinic.html
- ↑ http://www.openmedicinefoundation.org/scientific-advisory-board/
- ↑ Montoya JG, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE, Watt T, Kubo JT, Paik J, Desai M.(2013). Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. Journal of Medical Virology,85 (12):2101-9. doi: 10.1002/jmv.23713. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23959519
- ↑ Knox K, Carrigan D, Simmons G, Teque F, Zhou Y, Hackett J Jr, Qiu X, Luk KC, Schochetman G, Knox A, Kogelnik AM, Levy JA.(2011). No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science,333 (6038):94-7. doi: 10.1126/science.1204963. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21628393
- ↑ Kogelnik AM, Loomis K, Hoegh-Petersen M, Rosso F, Hischier C, Montoya JG. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. Journal of Clinical Virology,37 Suppl 1:S33-8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed /17276366
